TY - JOUR
T1 - Recent Trends and Developments in Multifunctional Nanoparticles for Cancer Theranostics
AU - Rabaan, Ali A.
AU - Bukhamsin, Rehab
AU - AlSaihati, Hajir
AU - Alshamrani, Saleh A.
AU - AlSihati, Jehad
AU - Al-Afghani, Hani M.
AU - Alsubki, Roua A.
AU - Abuzaid, Abdulmonem A.
AU - Al-Abdulhadi, Saleh
AU - Aldawood, Yahya
AU - Alsaleh, Abdulmonem A.
AU - Alhashem, Yousef N.
AU - Almatouq, Jenan A.
AU - Emran, Talha Bin
AU - Al-Ahmed, Shamsah H.
AU - Nainu, Firzan
AU - Mohapatra, Ranjan K.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12
Y1 - 2022/12
N2 - Conventional anticancer treatments, such as radiotherapy and chemotherapy, have significantly improved cancer therapy. Nevertheless, the existing traditional anticancer treatments have been reported to cause serious side effects and resistance to cancer and even to severely affect the quality of life of cancer survivors, which indicates the utmost urgency to develop effective and safe anticancer treatments. As the primary focus of cancer nanotheranostics, nanomaterials with unique surface chemistry and shape have been investigated for integrating cancer diagnostics with treatment techniques, including guiding a prompt diagnosis, precise imaging, treatment with an effective dose, and real-time supervision of therapeutic efficacy. Several theranostic nanosystems have been explored for cancer diagnosis and treatment in the past decade. However, metal-based nanotheranostics continue to be the most common types of nonentities. Consequently, the present review covers the physical characteristics of effective metallic, functionalized, and hybrid nanotheranostic systems. The scope of coverage also includes the clinical advantages and limitations of cancer nanotheranostics. In light of these viewpoints, future research directions exploring the robustness and clinical viability of cancer nanotheranostics through various strategies to enhance the biocompatibility of theranostic nanoparticles are summarised.
AB - Conventional anticancer treatments, such as radiotherapy and chemotherapy, have significantly improved cancer therapy. Nevertheless, the existing traditional anticancer treatments have been reported to cause serious side effects and resistance to cancer and even to severely affect the quality of life of cancer survivors, which indicates the utmost urgency to develop effective and safe anticancer treatments. As the primary focus of cancer nanotheranostics, nanomaterials with unique surface chemistry and shape have been investigated for integrating cancer diagnostics with treatment techniques, including guiding a prompt diagnosis, precise imaging, treatment with an effective dose, and real-time supervision of therapeutic efficacy. Several theranostic nanosystems have been explored for cancer diagnosis and treatment in the past decade. However, metal-based nanotheranostics continue to be the most common types of nonentities. Consequently, the present review covers the physical characteristics of effective metallic, functionalized, and hybrid nanotheranostic systems. The scope of coverage also includes the clinical advantages and limitations of cancer nanotheranostics. In light of these viewpoints, future research directions exploring the robustness and clinical viability of cancer nanotheranostics through various strategies to enhance the biocompatibility of theranostic nanoparticles are summarised.
KW - cancer therapy
KW - drug delivery
KW - nanomaterials
KW - nanotheranostics
KW - plasmonic nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85144583225&partnerID=8YFLogxK
U2 - 10.3390/molecules27248659
DO - 10.3390/molecules27248659
M3 - Review article
C2 - 36557793
AN - SCOPUS:85144583225
SN - 1420-3049
VL - 27
JO - Molecules
JF - Molecules
IS - 24
M1 - 8659
ER -
